After a fourth quarter in which revenue boomed throughout the biopharma industry, there were reversals for several drugmakers ...

Royal Bank of Canada dropped their price objective on Regeneron Pharmaceuticals from $1,051.00 to $943.00 and set an “outperform” rating on the stock in a report on Wednesday. Leerink Partners ...

Regeneron Pharmaceuticals previously stated that a macular disease patient support group, Good Days, closed funding support for Eylea recipients. That negatively impacted Eylea sales, Leerink ...

Mufg Securities Americas Inc. made a modest splash in the biotech pool, acquiring 1,554 shares of Regeneron Pharmaceuticals ...

Leonard Schleifer; Co-Chairman of the Board, President, Chief Executive Officer, Founder; Regeneron Pharmaceuticals Inc George Yancopoulos; Co-Chairman of the Board, President, Chief Scientific ...

A federal jury found Amgen liable for violating antitrust and tort laws. Elsewhere, Allogene and Kyverna trimmed staff and the FDA scheduled an advisory meeting.

Biotech company Regeneron (NASDAQ:REGN) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 3.7% year on year to $3.03 billion. Its non-GAAP profit of $8.22 per share was ...

After consecutive setbacks at the FDA, Regeneron's string of recent troubles with its Eylea franchise is continuing to pull down the drugmaker. Over the first three months of 2025, Regeneron's ...

On Monday, Leerink Partners initiated coverage on Akebia Therapeutics (NASDAQ: AKBA) stock with an Outperform rating and set a price target of $7.00.The coverage comes as Akebia’s stock shows ...